Skip to main content

Advertisement

Figure 6 | Molecular Pain

Figure 6

From: Impact of central and peripheral TRPV1 and ROS levels on proinflammatory mediators and nociceptive behavior

Figure 6

TRPV1 and ROS Mediated Increase in Inflammatory Mediators. A - COX-2 Staining Increase Is Blocked by ROS Scavenger PBN in SW982 Synoviocytes. Clonal SW982 synoviocytes are activated by TRPV1 agonist, resiniferatoxin, resulting in an increase in immunostaining for inflammatory mediator producing enzyme, COX-2. The COX-2 expression was blocked by either the TRP agonist capsazepine or the ROS scavenger, PBN, while the blockers alone had no effect. All experiments were done in triplicate. B- ROS Donor Induced TNFα Expression Increase Is Inhibited by TRPV1 Antagonist, SB-366791. Synoviocytes activated by ROS donor, tBOOH, also have increased immunoreactivity for the inflammatory mediator, TNFα, within 30 min that is significantly increased over control cultures. The effect of the tBOOH was reduced slightly by the TRPV1 antagonist, SB-366791. All experiments were done in triplicate and intensity measurements (arbitrary units) determined with the MetaVue computer-assisted imaging system.* p < 0.05 and ** p < 0.001 compared to the control cultures.

Back to article page